Skip to main content
SpringerLink
Log in

Adjuvant Systemic Therapy for Renal Cell Carcinoma

  • Chapter
  • First Online:
Kidney Cancer

  • 894 Accesses

Abstract

A significant proportion of patients undergoing nephrectomy for renal cell carcinoma remain at high risk of developing metastatic disease. Accurate staging and use of validated prognostic systems are helpful in estimating risk after surgery. At the current time, observation alone remains the standard-of-care after nephrectomy. Numerous systemic strategies have been investigated in the adjuvant setting. Treatment with interferon or interleukin-2, once the mainstay of treating advanced disease, has not shown any benefit in the adjuvant setting. Autologous tumor-derived vaccines have held promise as adjuvant therapy, but while improvements in tumor progression have been suggested in some trials, the data are difficult to interpret and no overall survival advantage has been proven. Small molecules targeting the VEGF and mTOR pathways have significant activity in metastatic renal carcinoma and have changed management of this stage of the disease. Many of these agents are currently being investigated in placebo-controlled adjuvant studies. While results of these trials are still several years away, there is optimism that these agents may prove effective and change the paradigm for treatment of localized renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. (2011) A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). http://clinicaltrials.gov/show/NCT00375674

  2. (2011) Everolimus in treating patients with kidney cancer who have undergone surgery.http://clinicaltrials.gov/ct/show/NCT01120249

  3. (2011) Monoclonal antibody therapy (Rencarex®) in treating patients who have undergone surgery for non-metastatic kidney cancer. http://clinicaltrials.gov/ct2/show/NCT00087022

  4. (2011) Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. http://clinicaltrials.gov/ct/show/NCT00492258

  5. (2011) Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). http://clinicaltrials.gov/ct2/show/NCT00116935

  6. (2011) A study to evaluate pazopanib as an adjuvant treatment for localized renal cell carcinoma (RCC) (PROTECT).http://clinicaltrials.gov/show/NCT01235962

  7. (2011) Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. http://clinicaltrials.gov/ct2/show/NCT00326898

  8. Hermanek P, Sobin LH (eds) (1987) TNM classification of malignant tumors. Springer, Berlin

    Google Scholar 

  9. (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 339: 1–15

    Google Scholar 

  10. Sobin LH, Wittekind CL (eds) (1997) TNM classification of malignant tumours. Wiley-Liss, New York

    Google Scholar 

  11. (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14–17

    Google Scholar 

  12. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds) (2002) AJCC cancer staging manual. Springer, New York

    Google Scholar 

  13. (2010) Kidney. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging manual. Springer, New York, pp 479–490

    Google Scholar 

  14. Adler A, Gillon G, Lurie H, Shaham J, Loven D, Shachter Y, Shani A, Servadio C, Stein JA (1987) Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod 6:610–624

    PubMed  CAS  Google Scholar 

  15. Aitchison M, Bray C, Van Poppel H, Sylvester R, Graham J, Innes C, McMahon L, Vasey PA (2008) Preliminary results from a randomized phase III trial of adjuvant interleukin-2, interferon alpha and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). J Clin Oncol 26(20 Suppl):5040

    Google Scholar 

  16. Allen MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore ME (2000) Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 83:980–985

    Article  PubMed  CAS  Google Scholar 

  17. Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, Menon M (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26:281–291

    Article  PubMed  Google Scholar 

  18. Asemissen AM, Brossart P (2009) Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother 58:1169–1174

    Article  PubMed  Google Scholar 

  19. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M (2001) IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85:1130–1136

    Article  PubMed  CAS  Google Scholar 

  20. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M (2005) Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92:843–846

    Article  PubMed  CAS  Google Scholar 

  21. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90:985–990

    Article  PubMed  CAS  Google Scholar 

  22. Bono AV, Benvenuti C, Gianneo E, Comeri GC, Roggia A (1979) Progestogens in renal cell carcinoma. A retrospective study. Eur Urol 5:94–96

    PubMed  CAS  Google Scholar 

  23. Cindolo L, Chiodini P, Gallo C, Ficarra V, Schips L, Tostain J, de La Taille A, Artibani W, Patard JJ (2008) Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 113:65–71

    Article  PubMed  Google Scholar 

  24. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21:3133–3140

    Article  PubMed  CAS  Google Scholar 

  25. Concolino G, Marocchi A, Conti C, Tenaglia R, Di Silverio F, Bracci U (1978) Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res 38:4340–4344

    PubMed  CAS  Google Scholar 

  26. Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM (2007) A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 7:13

    PubMed  Google Scholar 

  27. Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH, Bilous AM (2002) Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 94:658–664

    Article  PubMed  Google Scholar 

  28. Doehn C, Richter A, Theodor RA, Lehmacher W, Jocham D (2007) An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicenter phase-III trial [abstract #500]. J Urol 177(Suppl):167

    Google Scholar 

  29. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812–817

    Article  PubMed  CAS  Google Scholar 

  30. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  PubMed  CAS  Google Scholar 

  31. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318

    Article  PubMed  CAS  Google Scholar 

  32. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111

    Article  PubMed  Google Scholar 

  33. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690

    Article  PubMed  CAS  Google Scholar 

  34. Flocks RH, Kadesky MC (1958) Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol 79:196–201

    PubMed  CAS  Google Scholar 

  35. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395–2400

    Article  PubMed  Google Scholar 

  36. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H (2005) Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173:1889–1892

    Article  PubMed  Google Scholar 

  37. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688–696

    PubMed  CAS  Google Scholar 

  38. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77:2560–2566

    Article  PubMed  CAS  Google Scholar 

  39. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375:641–648

    Article  PubMed  CAS  Google Scholar 

  40. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    Article  PubMed  CAS  Google Scholar 

  41. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599

    Article  PubMed  CAS  Google Scholar 

  42. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166:63–67

    Article  PubMed  CAS  Google Scholar 

  43. Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Allhoff EP, Schips L, Zigeuner R, Figlin RA, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Lam JS (2007) Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol 178:35–40; discussion 40

    Article  PubMed  Google Scholar 

  44. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97:1663–1671

    Article  PubMed  Google Scholar 

  45. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG (2009) Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 73:337–341

    Article  PubMed  Google Scholar 

  46. Masuda F, Nakada J, Kondo I, Furuta N (1992) Adjuvant chemotherapy with vinblastine, adriamycin, and UFT for renal-cell carcinoma. Cancer Chemother Pharmacol 30:477–479

    Article  PubMed  CAS  Google Scholar 

  47. May M, Brookman-May S, Hoschke B, Gilfrich C, Kendel F, Baxmann S, Wittke S, Kiessig ST, Miller K, Johannsen M (2010) Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 59:687–695

    Article  PubMed  Google Scholar 

  48. McDermott DF, Ghebremichael MS, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP, Logan T, Figlin RA, Atkins MB, Group CW (2010) The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 28: (Suppl): Abstr 4514)

    Google Scholar 

  49. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–141

    Article  PubMed  CAS  Google Scholar 

  50. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21:1214–1222

    Article  PubMed  CAS  Google Scholar 

  51. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302–306

    Article  PubMed  CAS  Google Scholar 

  52. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265

    Article  PubMed  CAS  Google Scholar 

  53. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456

    Article  PubMed  CAS  Google Scholar 

  54. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590

    Article  PubMed  CAS  Google Scholar 

  55. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  56. Naito S, Kumazawa J, Omoto T, Iguchi A, Sagiyama K, Osada Y, Hiratsuka Y (1997) Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol 4:8–12

    Article  PubMed  CAS  Google Scholar 

  57. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 338:1272–1278

    Article  PubMed  CAS  Google Scholar 

  58. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110:2468–2477

    Article  PubMed  CAS  Google Scholar 

  59. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307–1317

    PubMed  CAS  Google Scholar 

  60. Passalacqua R, Buzio C, Buti S, Labianca R, Porta C, Boni C, Rondini E, Camisa R, Sabbatini R, Artioli C, Caminiti C (2007) Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). J Clin Oncol 25(20 Suppl):LBA5028

    Google Scholar 

  61. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22:3316–3322

    Article  PubMed  Google Scholar 

  62. Petkovic SD (1959) An anatomical classification of renal tumors in the adult as a basis for prognosis. J Urol 81:618–623

    PubMed  CAS  Google Scholar 

  63. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19:425–431

    PubMed  CAS  Google Scholar 

  64. Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E, Minervini S, Zanollo A, Fontanella U, Longo G et al (1987) Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 138:1379–1381

    PubMed  CAS  Google Scholar 

  65. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859–2867

    PubMed  CAS  Google Scholar 

  66. Repmann R, Goldschmidt AJ, Richter A (2003) Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res 23:969–974

    PubMed  CAS  Google Scholar 

  67. Repmann R, Wagner S, Richter A (1997) Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res 17:2879–2882

    PubMed  CAS  Google Scholar 

  68. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428

    Article  PubMed  CAS  Google Scholar 

  69. Robson CJ (1963) Radical nephrectomy for renal cell carcinoma. J Urol 89:37–42

    PubMed  CAS  Google Scholar 

  70. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301

    PubMed  CAS  Google Scholar 

  71. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664–8670

    Article  PubMed  Google Scholar 

  72. Satomi Y, Takai S, Kondo I, Fukushima S, Furuhata A (1982) Postoperative prophylactic use of progesterone in renal cell carcinoma. J Urol 128:919–922

    PubMed  CAS  Google Scholar 

  73. Sawczuk IS, Graham SDJ, Miesowicz F, Group AAS (1997) Randomized, controlled trial of adjuvant therapy with ex vivo activated T cells (ALT) in T1–3a,b,c or T4N+,M0 renal cell carcinoma (Meeting abstract). J Clin Oncol (Abstract 1163) vol. 16

    Google Scholar 

  74. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173:48–51

    Article  PubMed  Google Scholar 

  75. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068

    Article  PubMed  CAS  Google Scholar 

  76. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E (2010) Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 58:75–83

    Article  PubMed  CAS  Google Scholar 

  77. Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM (1996) Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19:184–191

    Article  PubMed  CAS  Google Scholar 

  78. Treisman JS, Morris R, Garlie N, Lefever A, Hanson JP (2008) Adjuvant activated T-cell (ATC) therapy for patients with non-metastatic or resected metastatic renal cell carcinoma. J Clin Oncol 26(20 Suppl):Abstract 5041

    Google Scholar 

  79. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163:1090–1095; quiz 1295

    Article  PubMed  CAS  Google Scholar 

  80. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372:145–154

    Article  PubMed  CAS  Google Scholar 

  81. Wood CG, Srivastava P, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Teofilovici F, Isakov L, Escudier B (2009) Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J Clin Invest 27(Suppl):3009

    Google Scholar 

  82. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22:42–60

    PubMed  CAS  Google Scholar 

  83. Yang S, de Souza P, Alemao E, Purvis J (2010) Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 102:1456–1460

    Article  PubMed  CAS  Google Scholar 

  84. Zigeuner R, Hutterer G, Chromecki T, Imamovic A, Kampel-Kettner K, Rehak P, Langner C, Pummer K (2010) External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 57:102–109

    Article  PubMed  Google Scholar 

  85. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649–1657

    PubMed  CAS  Google Scholar 

  86. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20:4559–4566

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA

    Christopher W. Ryan M.D.

Authors
  1. Christopher W. Ryan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher W. Ryan M.D. .

Editor information

Editors and Affiliations

  1. , Dept. of Internal Medicine, Division of, University of California School of Medic, X Street 4501, Sacramento, 95817, California, USA

    Primo N. Lara, Jr.

  2. , Department of Genitourinary Medical Onco, University of Texas MD Anderson Cancer C, Holcombe Blvd 1515, Houston, 77030, Texas, USA

    Eric Jonasch

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ryan, C.W. (2012). Adjuvant Systemic Therapy for Renal Cell Carcinoma. In: Lara, Jr., P., Jonasch, E. (eds) Kidney Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21858-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21858-3_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21857-6

  • Online ISBN: 978-3-642-21858-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation